Revlimid Approved With Safeguards Against Fetal Exposure
Education and prescribing safety program for Celgene’s Revlimid will restrict distribution and address risks of fetal exposure; the firm has ongoing studies to assess teratogenicity.
Education and prescribing safety program for Celgene’s Revlimid will restrict distribution and address risks of fetal exposure; the firm has ongoing studies to assess teratogenicity.